*Disseminated on Behalf of Oncolytics Biotech Inc. Please see disclosures below. |
| Oncolytics Biotech Makes a Big Announcement... |
| | | | | Hey Folks, Oncolytics Biotech (ONCY) reported promising results from their GOBLET trial testing pelareorep combined with atezolizumab in third-line anal cancer patients—a population with no FDA-approved treatment options.
The combination achieved a 29% response rate, nearly triple the roughly 10% typically seen in historical studies, with responses lasting around 17 months on average. Four of 14 patients responded, including two complete responses where the cancer was no longer detectable.
The company believes these results could support accelerated FDA approval and is planning a regulatory meeting in Q1 2026 to discuss a registration study.
If successful, this could offer a meaningful new option for patients who have exhausted other treatments.
Anyways...
That's all for now!
Until Next Time, -ZT Team | P.S. Want our text alerts? Text "ZIPTRADER" to 1-(855)-228-1598 to sign up!
(standard carrier data/text rates apply) |
|
|
|---|
|
*Disseminated on Behalf of Oncolytics Biotech Inc. Please see disclosures below. |
|
|---|
|
| | 5101 SANTA MONICA BLVD STE 8 #62, 90029, LOS ANGELES, CA |
| You've received it because you've subscribed to our newsletter or are a member of ZipTraderU. |
| This email was sent to stevenmagallanes520.nims@blogger.com |
| *SPONSORED CONTENT* ZipTrader LLC is a publishing company, we are not financial advisors. This is not financial advice. Investments involve risk and are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance. ZipTrader has been compensated fifteen thousand USD by ACH Bank Transfer by TD Media LLC to distribute media via email and SMS on behalf of Oncolytics Biotech Inc. (ONCY) from February 3, 2026 to February 4, 2026. ZipTrader may receive additional campaigns in the future by TD Media LLC to distribute media for Oncolytics Biotech Inc. (ONCY). As a result of this advertisement and other marketing efforts, ZipTrader may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of ZipTrader do not hold a position in Oncolytics Biotech Inc. (ONCY). This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Oncolytics Biotech Inc. (ONCY), increased trading volume, and possibly an increased share price of Oncolytics Biotech Inc. (ONCY), which may or may not be temporary and decrease once the marketing arrangement has ended. |
| BY READING THIS EMAIL & ALL ZIPTRADER CONTENT YOU AGREE: This is not financial advice. You must do your own due diligence on all information. ZIPTRADER LLC is a publishing company and we provide general information, opinions, & news coverage to viewers. However – we do not provide personalized financial advice, are not financial advisors, and our opinions are not suitable for all investors. You should not treat any opinion as expressed as a specific inducement to make a particular investment or follow a particular strategy, but just as an opinion. Use at your own risk. Past Performance is not indicative of future results, and any results presented are not typical, and should not be understood as typical. Actual results vary given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. TRADING IS RISKY: Most traders in all markets lose all of their money (and more if they use margin). Most small businesses fail. Do NOT partake in trading, investing, entrepreneurship or any other risky endeavor covered here if you are not prepared with the reality that most fail. We reserve the right to have affiliate relationships with advertisers/sponsors. See Full Terms of Service. See Our Advertisement Disclaimer. |
| | |
|
|
|---|
|
|
|
No comments:
Post a Comment